| Function: | Nervous System Drugs |
|---|---|
| Certification: | GMP, Reach, FDA |
| Grade Standard: | Medicine Grade |
| Type: | Chemical Reagent |
| State: | Solid |
| Volatile: | Not Volatile |
| Samples: |
|---|
Suppliers with verified business licenses
Audited Supplier | Identification | ||
| Name | Paroxetine hydrochloride | |
| Synonyms | (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride | |
| Molecular Structure |  |
|
| Molecular Formula | C19H20FNO3.HCl | |
| Molecular Weight | 365.83 | |
| CAS Registry Number | 78246-49-8 (110429-35-1) | |
Paroxetine is primarily used to treat major depressive disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder, panic disorder, agoraphobia, generalized anxiety disorder, premenstrual dysphoric disorder and menopausal hot flashes.
A variety of meta analyses have been conducted to evaluate the efficacy of paroxetine in depression. They have variously concluded that paroxetine is superior or equivalent to placebo and that it is equivalent or inferior to other antidepressants. Despite this, there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point.
Paroxetine was the first antidepressant approved in the United States for the treatment of panic disorder.[page needed] Several studies have concluded that paroxetine is superior to placebo in the treatment of panic disorder.
Paroxetine has demonstrated efficacy for the treatment of social anxiety disorder in adults and children. It is also beneficial for people with co-occurring social anxiety disorder and alcohol use disorder.It appears to be similar to a number of other SSRIs.
Paroxetine is used in the treatment of obsessive-compulsive disorder.Comparative efficacy of paroxetine is equivalent to that of clomipramine and venlafaxine. Paroxetine is also effective for children with obsessive-compulsive disorder.
Paroxetine is approved for treatment of PTSD in the United States, Japan and Europe.In the United States it is approved for short term use.
Paroxetine is also FDA-approved for Generalized anxiety disorder.
In 2013, low-dose paroxetine was approved in the US for the treatment of moderate-to-severe vasomotor symptoms such as hot flashes and night sweats associated with menopause. At the low dose used for menopausal hot flashes, side effects are similar to placebo and dose tapering is not required for discontinuation.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}